

Overall Evaluations of Carcinogenicity to Humans

As evaluated in IARC Monographs Volumes 1-88 (a total of 900 agents, mixtures and exposures)

This list contains all hazards evaluated to date, according to the type of hazard posed and to the type of exposure. Where appropriate, chemical abstract numbers are given [in square brackets]. For details of the evaluation, the relevant Monograph should be consulted (volume number given in round brackets, followed by year of publication of latest evaluation). Use a free-text search to find a particular compound.

Group 1: Carcinogenic to humans (95)

Agents and groups of agents

Aflatoxins (naturally occurring mixtures of) [1402-68-2] (Vol. 56, Vol. 82; 2002)

4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7; 1987)

Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl. 7; 1987)(NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)

Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987)

Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)

Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)

Benzidine [92-87-5] (Vol. 29, Suppl. 7; 1987)

Beryllium [7440-41-7] and beryllium compounds (Vol. 58; 1993)(NB: Evaluated as a group)

N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4, Suppl. 7; 1987)

Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2] (technical-grade) (Vol. 4, Suppl. 7; 1987)

1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4, Suppl. 7; 1987)

Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993)(NB: Evaluated as a group)

Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987)

1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7; 1987)

Chromium[VI] compounds (Vol. 49; 1990)(NB: Evaluated as a group)

Ciclosporin [79217-60-0] (Vol. 50; 1990)

Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7; 1987)

Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987)

Epstein-Barr virus (Vol. 70; 1997)

Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987)

Ethylene oxide [75-21-8] (Vol. 60; 1994)

(NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Etoposide [33419-42-0] in combination with cisplatin and bleomycin (Vol. 76; 2000)

Formaldehyde [50-00-0] (Vol. 88; in preparation)

[Gamma Radiation: see X- and Gamma (g)-Radiation]

Gallium arsenide [1303-00-0] (Vol. 86; in preparation)

Helicobacter pylori (infection with) (Vol. 61; 1994)

Hepatitis B virus (chronic infection with) (Vol. 59; 1994)

Hepatitis C virus (chronic infection with) (Vol. 59; 1994)

Herbal remedies containing plant species of the genus Aristolochia (Vol. 82; 2002)

Human immunodeficiency virus type 1 (infection with) (Vol. 67;1996)

Human papillomavirus type 16 (Vol. 64; 1995)

Human papillomavirus type 18 (Vol. 64; 1995)

Human T-cell lymphotropic virus type I (Vol. 67; 1996)

Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987)

8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation (Vol. 24, Suppl. 7; 1987)

MOPP and other combined chemotherapy including alkylating agents (Suppl. 7; 1987)

Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987)

2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7; 1987)

Neutrons (Vol. 75; 2000)(NB: Overall evaluation upgraded from 2B to 1 with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Nickel compounds (Vol. 49; 1990)(NB: Evaluated as a group)

Oestrogen therapy, postmenopausal (Vol. 72; 1999)

Oestrogens, nonsteroidal (Suppl. 7; 1987)(NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)

Oestrogens, steroidal (Suppl. 7; 1987) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)

Opisthorchis viverrini (infection with) (Vol. 61; 1994)

Oral contraceptives, combined (Vol. 72; 1999)(NB: There is also conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium)

Oral contraceptives, sequential (Suppl. 7; 1987)

Phosphorus-32, as phosphate (Vol. 78; 2001)

Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols (Vol. 78; 2001)

Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood) (Vol. 78; 2001)

Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001)(NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)

Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001)(NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)

Radium-224 and its decay products (Vol. 78; 2001)

Radium-226 and its decay products (Vol. 78; 2001)

Radium-228 and its decay products (Vol. 78; 2001)

Radon-222 [10043-92-2] and its decay products (Vol. 78; 2001)

Schistosoma haematobium (infection with) (Vol. 61; 1994)

Silica [14808-60-7], crystalline (inhaled in the form of quartz or cristobalite from occupational sources) (Vol. 68; 1997)

Solar radiation (Vol. 55; 1992)

Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)

Tamoxifen [10540-29-1] (Vol. 66; 1996)(NB: There is also conclusive evidence that this agent (tamoxifen) reduces the risk of contralateral breast cancer)

2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6] (Vol.69; 1997)(NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Thiotepa [52-24-4] (Vol. 50; 1990)

Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001)

Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987)

Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7; 1987)

X- and Gamma (g)-Radiation (Vol. 75; 2000)

Mixtures

Alcoholic beverages (Vol. 44; 1988)

Analgesic mixtures containing phenacetin (Suppl. 7; 1987)

Areca nut (Vol. 85; in preparation)

Betel quid with tobacco (Vol. 85; in preparation)

Betel quid without tobacco (Vol. 85; in preparation)

Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987)

Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987)

Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987)

Salted fish (Chinese-style) (Vol. 56; 1993)

Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987)

Soots (Vol. 35, Suppl. 7; 1987)

Tobacco products, smokeless (Vol. 37, Suppl. 7; 1987)

Wood dust (Vol. 62; 1995)

Exposure circumstances

Aluminium production (Vol. 34, Suppl. 7; 1987)

Arsenic in drinking-water (Vol. 84; in preparation)

Auramine, manufacture of (Suppl. 7; 1987)

Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987)

Coal gasification (Vol. 34, Suppl. 7; 1987)

Coke production (Vol. 34, Suppl. 7; 1987)

Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)

Haematite mining (underground) with exposure to radon (Vol. 1, Suppl. 7; 1987)

Involuntary smoking (Vol. 83; 2004)

Iron and steel founding (Vol. 34, Suppl. 7; 1987)

Isopropanol manufacture (strong-acid process) (Suppl. 7; 1987)

Magenta, manufacture of (Vol. 57; 1993)

Painter (occupational exposure as a) (Vol. 47; 1989)

Rubber industry (Vol. 28, Suppl. 7; 1987)

Strong-inorganic-acid mists containing sulfuric acid (occupational exposure to) (Vol. 54; 1992)

Tobacco smoking (Vol. 38, Suppl. 7, Vol. 83; 2004)

Group 2A: Probably carcinogenic to humans (66)

Agents and groups of agents

Acrylamide [79-06-1] (Vol. 60; 1994)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Androgenic (anabolic) steroids (Suppl. 7; 1987)

Aristolochic acids (naturally occurring mixtures of) (Vol. 82; 2002)

Azacitidine [320-67-2] (Vol. 50; 1990)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benzidine-based dyes (Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl.7; 1987)

1,3-Butadiene [106-99-0] (Vol. 71; 1999)

Captafol [2425-06-1] (Vol. 53; 1991)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Chloramphenicol [56-75-7] (Vol. 50; 1990)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

a-Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride [98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4] (combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999)

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4](Vol. 26, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

4-Chloro-ortho-toluidine [95-69-2] (Vol. 77; 2000)

Chlorozotocin [54749-90-5] (Vol. 50; 1990)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Clonorchis sinensis (infection with) (Vol. 61; 1994)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17, Suppl.7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Etoposide [33419-42-0] (Vol. 76; 2000)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Glycidol [556-52-5] (Vol. 77; 2000)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Human papillomavirus type 31 (Vol. 64; 1995)

Human papillomavirus type 33 (Vol. 64; 1995)

Indium phosphide [22398-80-7] (Vol. 86; in preparation)

IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6] (Vol. 56; 1993)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Lead compounds, inorganic (Vol. 87; in preparation)

Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol. 70; 1997)

5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

4,4'-Methylene bis(2-chloroaniline) (MOCA) [101-14-4] (Vol.57; 1993)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Methyl-N'-nitro-N-nitrosoguanidine(MNNG) [70-25-7] (Vol. 4, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Methyl-N-nitrosourea [684-93-5] (Vol. 17, Suppl.7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987)

N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987)

Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Teniposide [29767-20-2] (Vol. 76; 2000)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Tetrachloroethylene [127-18-4] (Vol. 63; 1995)

ortho-Toluidine [95-53-4] (Vol. 77; 2000)

Trichloroethylene [79-01-6] (Vol. 63; 1995)

1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995)

Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20, Suppl. 7, Vol. 71;1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation A (Vol. 55; 1992)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation B (Vol. 55; 1992)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ultraviolet radiation C (Vol. 55; 1992)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Vinyl fluoride [75-02-5] (Vol. 63; 1995)

Mixtures

Creosotes (from coal-tars) [8001-58-9] (Vol. 35, Suppl. 7; 1987)

Diesel engine exhaust (Vol. 46; 1989)

Hot mate (Vol. 51; 1991)

Non-arsenical insecticides (occupational exposures in spraying and application of) (Vol. 53; 1991)

Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl. 7; 1987)

Exposure circumstances

Art glass, glass containers and pressed ware (manufacture of) (Vol. 58; 1993)

Cobalt metal with tungsten carbide (Vol. 86; in preparation)

Hairdresser or barber (occupational exposure as a) (Vol. 57; 1993)

Petroleum refining (occupational exposures in) (Vol. 45; 1989)

Sunlamps and sunbeds (use of) (Vol. 55; 1992)

Group 2B: Possibly carcinogenic to humans (241)

Agents and groups of agents

- A-a-C (2-Amino-9H-pyrido[2,3-b]indole) [26148-68-5] (Vol. 40, Suppl. 7; 1987)
- Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)
- Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999)
- Acrylonitrile [107-13-1] (Vol. 71; 1999)
- AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7] (Vol.31, Suppl. 7; 1987)
- Aflatoxin M1 [6795-23-9] (Vol. 56; 1993)
- para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987)
- ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987)
- 2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol.7, Suppl. 7; 1987)
- Amsacrine [51264-14-3] (Vol. 76; 2000)
- ortho-Anisidine [90-04-0] (Vol. 73; 1999)
- Antimony trioxide [1309-64-4] (Vol. 47; 1989)
- Aramite® [140-57-8] (Vol. 5, Suppl. 7; 1987)
- Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7; 1987)
- Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987)
- Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)
- Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl. 7; 1987)
- Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7; 1987)
- Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7; 1987)
- Benzofuran [271-89-6] (Vol. 63; 1995)
- Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987)
- 2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol. 77; 2000)
- Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)
- Bracken fern (Vol. 40, Suppl. 7; 1987)
- Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999)
- Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl. 7;1987)
- b-Butyrolactone [3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)
- Caffeic acid [331-39-5] (Vol. 56; 1993)

Carbon black [1333-86-4] (Vol. 65; 1996)

Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Chlordane [57-74-9] (Vol. 79; 2001)

Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987)

Chlorendic acid [115-28-6] (Vol. 48; 1990)

para-Chloroaniline [106-47-8] (Vol. 57; 1993)

3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone [77439-76-0] (Vol. 84; in preparation)

Chloroform [67-66-3] (Vol. 73; 1999)

1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995)

Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987)

4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl.7; 1987)

Chloroprene [126-99-8] (Vol. 71; 1999)

Chlorothalonil [1897-45-6] (Vol. 73; 1999)

CI Acid Red 114 [6459-94-5] (Vol. 57; 1993)

CI Basic Red 9 [569-61-9] (Vol. 57; 1993)

CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993)

Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987)

Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991)(NB: Evaluated as a group)

Cobalt sulfate [10026-24-1] and other soluble cobalt(II) salts (Vol. 86; in preparation)

para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987)

Cycasin [14901-08-7] (Vol. 10, Suppl. 7; 1987)

Dacarbazine [4342-03-4] (Vol. 26, Suppl. 7; 1987)

Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) [117-10-2] (Vol.50; 1990)

Daunomycin [20830-81-3] (Vol. 10, Suppl. 7; 1987)

DDT [p,p'-DDT, 50-29-3] (Vol. 53; 1991)

N,N'-Diacetylbenzidine [613-35-4] (Vol. 16, Suppl.7; 1987)

2,4-Diaminoanisole [615-05-4] (Vol. 79; 2001)

4,4'-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl. 7; 1987)

2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987)

Dibenz[a,h]acridine [226-36-8] (Vol. 32, Suppl. 7; 1987)

Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl. 7; 1987)

7H-Dibenzo[c,g]carbazole [194-59-2] (Vol. 32, Suppl.7; 1987)

Dibenzo[a,e]pyrene [192-65-4] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7; 1987)

Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl. 7; 1987)

1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl. 7, Vol. 71; 1999)

2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000)

Dichloroacetic acid [79-43-6] (Vol. 84; in preparation)

para-Dichlorobenzene [106-46-7] (Vol. 73; 1999)

3,3'-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987)

3,3'-Dichloro-4,4'-diaminodiphenyl ether [28434-86-8] (Vol. 16,Suppl. 7; 1987)

1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Dichloromethane (methylene chloride) [75-09-2] (Vol. 71; 1999)

1,3-Dichloropropene [542-75-6] (technical-grade) (Vol. 41, Suppl.7, Vol. 71; 1999)

Dichlorvos [62-73-7] (Vol. 53; 1991)

1,2-Diethylhydrazine [1615-80-1] (Vol. 4, Suppl. 7, Vol. 71; 1999)

Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987)

Diisopropyl sulfate [2973-10-6] (Vol. 54, Vol. 71; 1999)

3,3'-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4](Vol. 4, Suppl. 7; 1987)

para-Dimethylaminoazobenzene [60-11-7] (Vol. 8, Suppl.7; 1987)

trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole [25962-77-0] (Vol. 7, Suppl. 7; 1987)

2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57; 1993)

3,3'-Dimethylbenzidine (ortho-Tolidine) [119-93-7] (Vol.1, Suppl. 7; 1987)

1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol. 71; 1999)

3,7-Dinitrofluoranthene [105735-71-5] (Vol. 65; 1996)

3,9-Dinitrofluoranthene [22506-53-2] (Vol. 65; 1996)

1,6-Dinitropyrene [42397-64-8] (Vol. 46; 1989)

1,8-Dinitropyrene [42397-65-9] (Vol. 46; 1989)

2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996)

2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996)

1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Disperse Blue 1 [2475-45-8] (Vol. 48; 1990)

1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Ethylbenzene [100-41-4] (Vol. 77; 2000)

Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987)

Foreign bodies, implanted in tissues (Vol. 74; 1999)

Polymeric, prepared as thin smooth films (with the exception of poly(glycolic acid))
Metallic, prepared as thin smooth films
Metallic cobalt, metallic nickel and an alloy powder containing 66-67% nickel, 13-16% chromium and 7% iron

2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [3570-75-0](Vol. 7, Suppl. 7; 1987)

Fumonisin B1 [116355-83-0] (Vol. 82; 2002)

Furan [110-00-9] (Vol. 63; 1995)

Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole) [67730-11-4] (Vol. 40, Suppl. 7; 1987)

Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)[67730-10-3] (Vol. 40, Suppl. 7; 1987)

Glyceraldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Griseofulvin [126-07-8] (Vol. 79; 2001)

HC Blue No. 1 [2784-94-3] (Vol. 57; 1993)

Heptachlor [76-44-8] (Vol. 79; 2001)

Hexachlorobenzene [118-74-1] (Vol. 79; 2001)

Hexachloroethane [67-72-1] (Vol. 73; 1999)

Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987)

Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Human immunodeficiency virus type 2 (infection with) (Vol. 67;1996)

Human papillomaviruses: some types other than 16, 18, 31 and 33 (Vol. 64; 1995)

Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999)

1-Hydroxyanthraquinone [129-43-1] (Vol. 82; 2002)

Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl. 7; 1987)

Iron-dextran complex [9004-66-4] (Vol. 2, Suppl. 7; 1987)

Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999)

Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987)

Lead [7439-92-1] (Vol. 23, Suppl.7; 1987)

Magenta [632-99-5] (containing CI Basic Red 9) (Vol. 57; 1993)

Magnetic fields (extremely low-frequency) (Vol. 80; 2002)

MeA-a-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) [68006-83-7] (Vol. 40, Suppl. 7; 1987)

Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl. 7; 1987)

MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) [77094-11-2] (Vol. 56; 1993)

MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) [77500-04-0] (Vol. 56; 1993)

Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987)

2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl. 7, Vol. 71; 1999)

Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl. 7; 1987)

5-Methylchrysene [3697-24-3] (Vol. 32, Suppl. 7; 1987)

4,4'-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4, Suppl.7; 1987)

4,4'-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7; 1987)

Methylmercury compounds (Vol. 58; 1993)
(NB: Evaluated as a group)

2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity) (Vol.27, Suppl. 7; 1987)

N-Methyl-N-nitrosourethane [615-53-2] (Vol. 4, Suppl.7; 1987)

Methylthiouracil [56-04-2] (Vol. 79; 2001)

Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987)

Mirex [2385-85-5] (Vol. 20, Suppl. 7; 1987)

Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987)

Mitoxantrone [65271-80-9] (Vol. 76; 2000)

Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987)

5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone [3795-88-8] (Vol. 7, Suppl. 7; 1987)

Nafenopin [3771-19-5] (Vol. 24, Suppl. 7; 1987)

Naphthalene [91-20-3] (Vol. 82; 2002)

Nickel, metallic [7440-02-0] and alloys (Vol. 49; 1990)

Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987)

Nitriiotriacetic acid [139-13-9] and its salts (Vol. 73; 1999)(NB: Evaluated as a group)

5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987)

2-Nitroanisole [91-23-6] (Vol. 65; 1996)

Nitrobenzene [98-95-3] (Vol. 65; 1996)

6-Nitrochrysene [7496-02-8] (Vol. 46; 1989)

Nitrofen [1836-75-5] (technical-grade) (Vol. 30, Suppl. 7; 1987)

2-Nitrofluorene [607-57-8] (Vol. 46; 1989)

1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0] (Vol.7, Suppl. 7; 1987)

N-[4-(5-Nitro-2-furyl)-2-thiazoly]acetamide [531-82-8] (Vol. 7, Suppl. 7; 1987)

Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl. 7;1987)

Nitromethane [75-52-5] (Vol. 77; 2000)

2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999)

1-Nitropyrene [5522-43-0] (Vol. 46; 1989)

4-Nitropyrene [57835-92-4] (Vol. 46; 1989)

N-Nitrosodi-n-butylamine [924-16-3] (Vol. 17, Suppl.7; 1987)

N-Nitrosodiethanolamine [1116-54-7] (Vol. 17, Suppl. 7, Vol. 77;2000)

N-Nitrosodi-n-propylamine [621-64-7] (Vol. 17, Suppl.7; 1987)

3-(N-Nitrosomethylamino)propionitrile [60153-49-3] (Vol. 85; in preparation)

4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK)[64091-91-4] (Vol. 37, Suppl. 7; 1987)

N-Nitrosomethylethylamine [10595-95-6] (Vol. 17, Suppl.7; 1987)

N-Nitrosomethylvinylamine [4549-40-0] (Vol. 17, Suppl.7; 1987)

N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7; 1987)

N'-Nitrosornicotine (NNN) [16543-55-8] (Vol. 37, Suppl. 7;1987)

N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl. 7; 1987)

N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl. 7; 1987)

N-Nitrososarcosine [13256-22-9] (Vol. 17, Suppl. 7; 1987)

Ochratoxin A [303-47-9] (Vol. 56; 1993)

Oestrogen-progesterone therapy, postmenopausal (Vol. 72; 1999)

Oil Orange SS [2646-17-5] (Vol. 8, Suppl. 7; 1987)

Oxazepam [604-75-1] (Vol. 66; 1996)

Palygorskite (attapulgite) [12174-11-7] (long fibres, > 5 micrometers) (Vol. 68; 1997)

Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine)
(Vol. 24, Suppl. 7; 1987)

Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl. 7; 1987)

Phenobarbital [50-06-6] (Vol. 79; 2001)

Phenolphthalein [77-09-8] (Vol. 76; 2000)

Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl. 7; 1987)

Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999)

Phenytoin [57-41-0] (Vol. 66; 1996)

PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) [105650-23-5] (Vol. 56; 1993)

Polychlorophenols and their sodium salts (mixed exposures) (Vol. 41, Suppl. 7, Vol. 53, Vol. 71; 1999)

Ponceau MX [3761-53-3] (Vol. 8, Suppl. 7; 1987)

Ponceau 3R [3564-09-8] (Vol. 8, Suppl. 7; 1987)

Potassium bromate [7758-01-2] (Vol. 73; 1999)

Progestins (Suppl. 7; 1987)

Progestogen-only contraceptives (Vol. 72; 1999)

1,3-Propane sultone [1120-71-4] (Vol. 4, Suppl. 7, Vol. 71; 1999)

b-Propiolactone [57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)

Propylene oxide [75-56-9] (Vol. 60; 1994)

Propylthiouracil [51-52-5] (Vol. 79; 2001)

Refractory ceramic fibres (Vol. 43, Vol. 81; 2002)

Riddelliine [23246-96-0] (Vol. 10, Suppl. 7, Vol. 82; 2002)

Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987)

Schistosoma japonicum (infection with) (Vol. 61; 1994)

Sodium ortho-phenylphenate [132-27-4] (Vol. 73; 1999)

Special-purpose fibres such as E-glass and '475' glass fibres (Vol. 81; 2002)

Sterigmatocystin [10048-13-2] (Vol. 10, Suppl. 7; 1987)

Streptozotocin [18883-66-4] (Vol. 17, Suppl. 7; 1987)

Styrene [100-42-5] (Vol. 60, 82; 2002)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987)

Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Tetranitromethane [509-14-8] (Vol. 65; 1996)

Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987)

4,4'-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987)

Thiouracil [141-90-2] (Vol. 79; 2001)

Toluene diisocyanates [26471-62-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol. 50; 1990)

Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)[62450-06-0] (Vol. 31, Suppl. 7; 1987)

Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole)[62450-07-1] (Vol. 31, Suppl. 7; 1987)

Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987)

Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987)

Urethane [51-79-6] (Vol. 7, Suppl. 7; 1987)

Vanadium pentoxide [1314-62-1] (Vol. 86; in preparation)

Vinyl acetate [108-05-4] (Vol. 63; 1995)

4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994)

4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994)

Zalcitabine [7481-89-2] (Vol. 76; 2000)

Zidovudine (AZT) [30516-87-1] (Vol. 76; 2000)

Mixtures

Bitumens [8052-42-4], extracts of steam-refined and air-refined (Vol. 35, Suppl. 7; 1987)

Carrageenan [9000-07-1], degraded (Vol. 31, Suppl. 7; 1987)

Chlorinated paraffins of average carbon chain length C12 and average degree of chlorination approximately 60% (Vol. 48; 1990)

Coffee (urinary bladder) (Vol. 51; 1991)(NB: There is some evidence of an inverse relationship between coffee drinking and cancer of the large bowel; coffee drinking could not be classified as to its carcinogenicity to other organs)

Diesel fuel, marine (Vol. 45; 1989)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Engine exhaust, gasoline (Vol. 46; 1989)

Fuel oils, residual (heavy) (Vol. 45; 1989)

Gasoline (Vol. 45; 1989)(NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other data relevant to the evaluation of carcinogenicity and its mechanisms)

Pickled vegetables (traditional in Asia) (Vol. 56; 1993)

Polybrominated biphenyls [Firemaster BP-6, 59536-65-1] (Vol. 41, Suppl. 7; 1987)

Toxaphene (Polychlorinated camphenes) [8001-35-2] (Vol. 79; 2001)

Toxins derived from *Fusarium moniliforme* (Vol. 56; 1993)

Welding fumes (Vol. 49; 1990)

Exposure circumstances

Carpentry and joinery (Vol. 25, Suppl. 7; 1987)

Cobalt metal without tungsten carbide (Vol. 86; in preparation)

Dry cleaning (occupational exposures in) (Vol. 63; 1995)

Printing processes (occupational exposures in) (Vol. 65; 1996)

Textile manufacturing industry (work in) (Vol. 48; 1990)

Group 3: Not classifiable as to carcinogenicity to humans (497)

Agents and groups of agents

Aciclovir [59277-89-3] (Vol. 76; 2000)

Acridine orange [494-38-2] (Vol. 16, Suppl. 7; 1987)

Acriflavinium chloride [8018-07-3] (Vol. 13, Suppl. 7; 1987)

Acrolein [107-02-8] (Vol. 63; 1995)

Acrylic acid [79-10-7] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Acrylic fibres (Vol. 19, Suppl. 7; 1987)

Acrylonitrile-butadiene-styrene copolymers (Vol. 19, Suppl. 7; 1987)

Actinomycin D [50-76-0] (Vol. 10, Suppl. 7; 1987)

Agaricine [2757-90-6] (Vol. 31, Suppl. 7; 1987)

Aldicarb [116-06-3] (Vol. 53; 1991)

Aldrin [309-00-2] (Vol. 5, Suppl. 7; 1987)

Allyl chloride [107-05-1] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Allyl isothiocyanate [57-06-7] (Vol. 73; 1999)

Allyl isovalerate [2835-39-4] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Amaranth [915-67-3] (Vol. 8, Suppl. 7; 1987)

5-Aminoacenaphthene [4657-93-6] (Vol. 16, Suppl. 7; 1987)

2-Aminoanthraquinone [117-79-3] (Vol. 27, Suppl. 7; 1987)

para-Aminobenzoic acid [150-13-0] (Vol. 16, Suppl. 7; 1987)

1-Amino-2-methylantraquinone [82-28-0] (Vol. 27, Suppl. 7; 1987)

2-Amino-4-nitrophenol [99-57-0] (Vol. 57; 1993)

2-Amino-5-nitrophenol [121-88-0] (Vol. 57; 1993)

4-Amino-2-nitrophenol [119-34-6] (Vol. 16, Suppl. 7; 1987)

2-Amino-5-nitrothiazole [121-66-4] (Vol. 31, Suppl. 7; 1987)

11-Aminoundecanoic acid [2432-99-7] (Vol. 39, Suppl. 7; 1987)

Amitrole [61-82-5] (Vol. 79; 2001)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

Ampicillin [69-53-4] (Vol. 50; 1990)

Anaesthetics, volatile (Vol. 11, Suppl. 7; 1987)

Angelicin [523-50-2] plus ultraviolet A radiation (Vol. 40, Suppl.7; 1987)

Aniline [62-53-3] (Vol. 27, Suppl. 7; 1987)

para-Anisidine [104-94-9] (Vol. 27, Suppl. 7; 1987)

Anthanthrene [191-26-4] (Vol. 32, Suppl. 7; 1987)

Anthracene [120-12-7] (Vol. 32, Suppl. 7; 1987)

Anthranilic acid [118-92-3] (Vol. 16, Suppl. 7; 1987)

Antimony trisulfide [1345-04-6] (Vol. 47; 1989)

Apholate [52-46-0] (Vol. 9, Suppl. 7; 1987)

para-Aramid fibrils [24938-64-5] (Vol. 68; 1997)

Atrazine [1912-24-9] (Vol. 73; 1999)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

Aurothioglucose [12192-57-3] (Vol. 13, Suppl. 7; 1987)

2-(1-Aziridinyl)ethanol [1072-52-2] (Vol. 9, Suppl. 7; 1987)

Aziridyl benzoquinone [800-24-8] (Vol. 9, Suppl. 7; 1987)

Azobenzene [103-33-3] (Vol. 8, Suppl. 7; 1987)

Benz[a]acridine [225-11-6] (Vol. 32, Suppl. 7; 1987)

Benz[c]acridine [225-51-4] (Vol. 32, Suppl. 7; 1987)

Benzo[ghi]fluoranthene [203-12-3] (Vol. 32, Suppl. 7; 1987)

Benzo[a]fluorene [238-84-6] (Vol. 32, Suppl. 7; 1987)

Benzo[b]fluorene [243-17-4] (Vol. 32, Suppl. 7; 1987)

Benzo[c]fluorene [205-12-9] (Vol. 32, Suppl. 7; 1987)

Benzo[ghi]perylene [191-24-2] (Vol. 32, Suppl. 7; 1987)

Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl. 7; 1987)

Benzo[e]pyrene [192-97-2] (Vol. 32, Suppl. 7; 1987)

para-Benzoquinone dioxime [105-11-3] (Vol. 29, Suppl. 7, Vol. 71; 1999)

Benzoyl peroxide [94-36-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Benzyl acetate [140-11-4] (Vol. 40, Suppl. 7, Vol. 71; 1999)

Bis(1-aziridinyl)morpholinophosphine sulfide [2168-68-5] (Vol.9, Suppl. 7; 1987)

Bis(2-chloroethyl)ether [111-44-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)

1,2-Bis(chloromethoxy)ethane [13483-18-6] (Vol. 15; Suppl. 7, Vol. 71; 1999)

1,4-Bis(chloromethoxymethyl)benzene [56894-91-8] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Bis(2-chloro-1-methylethyl)ether [108-60-1] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Bis(2,3-epoxycyclopentyl)ether [2386-90-5] (Vol. 47, Vol. 71; 1999)

Bisphenol A diglycidyl ether (Araldite®) [1675-54-3] (Vol. 47, Vol. 71; 1999)

Bisulfites (Vol. 54; 1992)

Blue VRS [129-17-9] (Vol. 16, Suppl. 7; 1987)

Brilliant Blue FCF, disodium salt [3844-45-9] (Vol. 16, Suppl.7; 1987)

Bromochloroacetonitrile [83463-62-1] (Vol. 52, Vol. 71; 1999)

Bromoethane [74-96-4] (Vol. 52, Vol. 71; 1999)

Bromoform [75-25-2] (Vol. 52, Vol. 71; 1999)

2-Butoxyethanol [111-76-2] (Vol. 88; in preparation)

1-tert-Butoxy-2-propanol [57018-52-7] (Vol. 88; in preparation)

n-Butyl acrylate [141-32-2] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Butylated hydroxytoluene (BHT) [128-37-0] (Vol. 40, Suppl. 7;1987)

Butyl benzyl phthalate [85-68-7] (Vol. 73; 1999)

g-Butyrolactone [96-48-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Caffeine [58-08-2] (Vol. 51; 1991)

Cantharidin [56-25-7] (Vol. 10, Suppl. 7; 1987)

Captan [133-06-2] (Vol. 30, Suppl. 7; 1987)

Carbaryl [63-25-2] (Vol. 12, Suppl. 7; 1987)

Carbazole [86-74-8] (Vol. 32, Suppl. 7, Vol. 71; 1999)

3-Carbethoxyorsoralen [20073-24-9] (Vol. 40, Suppl. 7; 1987)

Carmoisine [3567-69-9] (Vol. 8, Suppl. 7; 1987)

Carrageenan [9000-07-1], native (Vol. 31, Suppl. 7; 1987)

Chloral [75-87-6] (Vol. 63; 1995)

Chloral hydrate [302-17-0] (Vol. 84; in preparation)

Chloramine [10599-90-3] (Vol. 84; in preparation)

Chlordimeform [6164-98-3] (Vol. 30, Suppl. 7; 1987)

Chlorinated drinking-water (Vol. 52; 1991)

Chloroacetonitrile [107-14-2] (Vol. 52, Vol. 71; 1999)

Chlorobenzilate [510-15-6] (Vol. 30, Suppl. 7; 1987)

Chlorodibromomethane [124-48-1] (Vol. 52, Vol. 71; 1999)

Chlorodifluoromethane [75-45-6] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Chloroethane [75-00-3] (Vol. 52, Vol. 71; 1999)

Chlorofluoromethane [593-70-4] (Vol. 41, Suppl. 7, Vol. 71; 1999)

3-Chloro-2-methylpropene [563-47-3] (Vol. 63; 1995)

4-Chloro-meta-phenylenediamine [5131-60-2] (Vol. 27, Suppl.7; 1987)

Chloronitrobenzenes [88-73-3; 121-73-3; 100-00-5] (Vol. 65; 1996)

Chloroprotham [101-21-3] (Vol. 12, Suppl. 7; 1987)

Chloroquine [54-05-7] (Vol. 13, Suppl. 7; 1987)

5-Chloro-ortho-toluidine [95-79-4] (Vol. 77; 2000)

2-Chloro-1,1,1-trifluoroethane [75-88-7] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Cholesterol [57-88-5] (Vol. 31, Suppl. 7; 1987)

Chromium[III] compounds (Vol. 49; 1990)

Chromium [7440-47-3], metallic (Vol. 49; 1990)

Chrysene [218-01-9] (Vol. 32, Suppl. 7; 1987)

Chrysoidine [532-82-1] (Vol. 8, Suppl. 7; 1987)

CI Acid Orange 3 [6373-74-6] (Vol. 57; 1993)

Cimetidine [51481-61-9] (Vol. 50; 1990)

Cinnamyl anthranilate [87-29-6] (Vol. 77; 2000)

CI Pigment Red 3 [2425-85-6] (Vol. 57; 1993)

Citrinin [518-75-2] (Vol. 40, Suppl. 7; 1987)

Clofibrate [637-07-0] (Vol. 66; 1996)

Clomiphene citrate [50-41-9] (Vol. 21, Suppl. 7; 1987)

Coal dust (Vol. 68; 1997)

Continuous glass filament (Vol. 43, Vol. 81; 2002)

Copper 8-hydroxyquinoline [10380-28-6] (Vol. 15, Suppl. 7; 1987)

Coronene [191-07-1] (Vol. 32, Suppl. 7; 1987)

Coumarin [91-64-5] (Vol. 77; 2000)

meta-Cresidine [102-50-1] (Vol. 27, Suppl. 7; 1987)

Crotonaldehyde [4170-30-3] (Vol. 63; 1995)

Cyclamates [sodium cyclamate, 139-05-9] (Vol. 73; 1999)

Cyclochlorotine [12663-46-6] (Vol. 10, Suppl. 7; 1987)

Cyclohexanone [108-94-1] (Vol. 47, Vol. 71; 1999)

Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl. 7; 1987)

D & C Red No. 9 [5160-02-1] (Vol. 57; 1993)

Dapsone [80-08-0] (Vol. 24, Suppl. 7; 1987)

Decabromodiphenyl oxide [1163-19-5] (Vol. 48, Vol. 71; 1999)

Deltamethrin [52918-63-5] (Vol. 53; 1991)

Diacetylaminoazotoluene [83-63-6] (Vol. 8, Suppl. 7; 1987)

Diallate [2303-16-4] (Vol. 30, Suppl. 7; 1987)

1,2-Diamino-4-nitrobenzene [99-56-9] (Vol. 16, Suppl. 7; 1987)

1,4-Diamino-2-nitrobenzene [5307-14-2] (Vol. 57; 1993)

2,5-Diaminotoluene [95-70-5] (Vol. 16, Suppl. 7; 1987)

Diazepam [439-14-5] (Vol. 66; 1996)

Diazomethane [334-88-3] (Vol. 7, Suppl. 7; 1987)

Dibenz[a,c]anthracene [215-58-7] (Vol. 32, Suppl. 7; 1987)

Dibenz[a,j]anthracene [224-41-9] (Vol. 32, Suppl. 7; 1987)

Dibenzo-para-dioxin (Vol. 69; 1997)

Dibenzo[a,e]fluoranthene [5385-75-1] (Vol. 32, Suppl. 7;1987)

Dibenzo[h,rst]pentaphene [192-47-2] (Vol. 3, Suppl. 7;1987)

Dibromoacetonitrile [3252-43-5] (Vol. 52, Vol. 71; 1999)

Dichloroacetonitrile [3018-12-0] (Vol. 52, Vol. 71; 1999)

Dichloroacetylene [7572-29-4] (Vol. 39, Suppl. 7, Vol. 71; 1999)

meta-Dichlorobenzene [541-73-1] (Vol. 73; 1999)

ortho-Dichlorobenzene [95-50-1] (Vol. 73; 1999)

trans-1,4-Dichlorobutene [110-57-6] (Vol. 15, Suppl. 7, Vol. 71; 1999)

2,6-Dichloro-para-phenylenediamine [609-20-1] (Vol. 39,Suppl. 7; 1987)

1,2-Dichloropropane [78-87-5] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Dicofol [115-32-2] (Vol. 30, Suppl. 7; 1987)

Didanosine [69655-05-6] (Vol. 76; 2000)

Dieldrin [60-57-1] (Vol. 5, Suppl. 7; 1987)

Diethanolamine [111-42-2] (Vol. 77; 2000)

Di(2-ethylhexyl) adipate [103-23-1] (Vol. 77; 2000)

Di(2-ethylhexyl) phthalate [117-81-7] (Vol. 77; 2000)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

N,N'-Diethylthiourea [105-55-5] (Vol. 79; 2001)

Dihydroxymethylfuratrizine [794-93-4] (Vol. 24, Suppl. 7; 1987)

Dimethoxane [828-00-2] (Vol. 15, Suppl. 7; 1987)

3,3'-Dimethoxybenzidine-4,4'-diisocyanate [91-93-0] (Vol. 39,Suppl. 7; 1987)

para-Dimethylaminoazobenzenediazo sodium sulfonate [140-56-7](Vol. 8, Suppl. 7; 1987)

4,4'-Dimethylangelicin [22975-76-4] plus ultraviolet A radiation(Suppl. 7; 1987)

4,5'-Dimethylangelicin [4063-41-6] plus ultraviolet A radiation(Suppl. 7; 1987)

N,N-Dimethylaniline [121-69-7] (Vol. 57; 1993)

Dimethylformamide [68-12-2] (Vol. 47; Vol. 71; 1999)

Dimethyl hydrogen phosphite [868-85-9] (Vol. 48, Vol. 71; 1999)

1,4-Dimethylphenanthrene [22349-59-3] (Vol. 32, Suppl. 7; 1987)

1,3-Dinitropyrene [75321-20-9] (Vol. 46; 1989)

3,5-Dinitrotoluene [618-85-9] (Vol. 65; 1996)

Dinitrosopentamethylenetetramine [101-25-7] (Vol. 11, Suppl. 7; 1987)

2,4'-Diphenyldiamine [492-17-1] (Vol. 16, Suppl. 7; 1987)

Disperse Yellow 3 [2832-40-8] (Vol. 48; 1990)

Disulfiram [97-77-8] (Vol. 12, Suppl. 7; 1987)

Dithranol [1143-38-0] (Vol. 13; Suppl. 7; 1987)

Doxefazepam [40762-15-0] (Vol. 66; 1996)

Doxylamine succinate [562-10-7] (Vol. 79; 2001)

Droloxifene [82413-20-5] (Vol. 66; 1996)

Dulcin [150-69-6] (Vol. 12, Suppl. 7; 1987)

Electric fields (extremely low-frequency) (Vol. 80; 2002)

Electric fields (static) (Vol. 80; 2002)

Endrin [72-20-8] (Vol. 5, Suppl. 7; 1987)

Eosin [15086-94-9] (Vol. 15, Suppl. 7; 1987)

3,4-Epoxy-6-methylcyclohexylmethyl-3,4-epoxy-6-methylcyclo-hexanecarboxylate [141-37-7](Vol. 11, Suppl. 7, Vol. 71; 1999)

cis-9,10-Epoxystearic acid [2443-39-2] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Estazolam [29975-16-4] (Vol. 66; 1996)

Ethionamide [536-33-4] (Vol. 13, Suppl. 7; 1987)

Ethylene [74-85-1] (Vol. 60; 1994)

Ethylene sulfide [420-12-2] (Vol. 11, Suppl. 7; 1987)

Ethylenethiourea [96-45-7] (Vol. 79; 2001)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

2-Ethylhexyl acrylate [103-11-7] (Vol. 60; 1994)

Ethyl selenac [5456-28-0] (Vol. 12, Suppl. 7; 1987)

Ethyl tellurac [20941-65-5] (Vol. 12, Suppl. 7; 1987)

Eugenol [97-53-0] (Vol. 36, Suppl. 7; 1987)

Evans blue [314-13-6] (Vol. 8, Suppl. 7; 1987)

Fast Green FCF [2353-45-9] (Vol. 16, Suppl. 7; 1987)

Fenvalerate [51630-58-1] (Vol. 53; 1991)

Ferbam [14484-64-1] (Vol. 12, Suppl. 7; 1987)

Ferric oxide [1309-37-1] (Vol. 1, Suppl. 7; 1987)

Fluometuron [2164-17-2] (Vol. 30, Suppl. 7; 1987)

Fluoranthene [206-44-0] (Vol. 32, Suppl. 7; 1987)

Fluorene [86-73-7] (Vol. 32, Suppl. 7; 1987)

Fluorescent lighting (Vol. 55; 1992)

Fluorides (inorganic, used in drinking-water) (Vol. 27, Suppl.7; 1987)

5-Fluorouracil [51-21-8] (Vol. 26, Suppl. 7; 1987)

Foreign bodies, implanted in tissues (Vol. 74; 1999)

Metallic chromium or titanium, cobalt-based, chromium-based and titanium-based alloys, stainless steel and depleted uranium

Furazolidone [67-45-8] (Vol. 31, Suppl. 7; 1987)

Furfural [98-01-1] (Vol. 63; 1995)

Furosemide (Frusemide) [54-31-9] (Vol. 50; 1990)

Gemfibrozil [25812-30-0] (Vol. 66; 1996)

Glycidyl oleate [5431-33-4] (Vol. 11, Suppl. 7; 1987)

Glycidyl stearate [7460-84-6] (Vol. 11, Suppl. 7; 1987)

Guinea Green B [4680-78-8] (Vol. 16, Suppl. 7; 1987)

Gyromitrin [16568-02-8] (Vol. 31, Suppl. 7; 1987)

Haematite [1317-60-8] (Vol. 1, Suppl. 7; 1987)

HC Blue No. 2 [33229-34-4] (Vol. 57; 1993)

HC Red No. 3 [2871-01-4] (Vol. 57; 1993)

HC Yellow No. 4 [59820-43-8] (Vol. 57; 1993)

Hepatitis D virus (Vol. 59; 1994)

Hexachlorobutadiene [87-68-3] (Vol. 73; 1999)

Hexachlorophene [70-30-4] (Vol. 20, Suppl. 7; 1987)

Human T-cell lymphotropic virus type II (Vol. 67; 1996)

Hycanthone mesylate [23255-93-8] (Vol. 13, Suppl. 7; 1987)

Hydralazine [86-54-4] (Vol. 24, Suppl. 7; 1987)

Hydrochloric acid [7647-01-0] (Vol. 54; 1992)

Hydrochlorothiazide [58-93-5] (Vol. 50; 1990)

Hydrogen peroxide [7722-84-1] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Hydroquinone [123-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)

4-Hydroxyazobenzene [1689-82-3] (Vol. 8, Suppl. 7; 1987)

8-Hydroxyquinoline [148-24-3] (Vol. 13, Suppl. 7; 1987)

Hydroxysenkirkine [26782-43-4] (Vol. 10, Suppl. 7; 1987)

Hydroxyurea [127-07-1] (Vol. 76; 2000)

Hypochlorite salts (Vol. 52; 1991)

Insulation glass wool (Vol. 43, Vol. 81; 2002)

Iron-dextrin complex [9004-51-7] (Vol. 2, Suppl. 7; 1987)

Iron sorbitol-citric acid complex [1338-16-5] (Vol. 2, Suppl.7; 1987)

Isatidine [15503-86-3] (Vol. 10, Suppl. 7; 1987)

Isonicotinic acid hydrazide (Isoniazid) [54-85-3] (Vol. 4, Suppl.7; 1987)

Isophosphamide [3778-73-2] (Vol. 26, Suppl. 7; 1987)

Isopropanol [67-63-0] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Isopropyl oils (Vol. 15, Suppl. 7, Vol. 71; 1999)

Isosafrole [120-58-1] (Vol. 10, Suppl. 7; 1987)

Jacobine [6870-67-3] (Vol. 10, Suppl. 7; 1987)

Kaempferol [520-18-3] (Vol. 31, Suppl. 7; 1987)

Kojic acid [501-30-4] (Vol. 79; 2001)

Lauroyl peroxide [105-74-8] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Lead compounds, organic (Vol. 23, Suppl. 7, Vol. 87; in preparation)

Light Green SF [5141-20-8] (Vol. 16, Suppl. 7; 1987)

d-Limonene [5989-27-5] (Vol. 73; 1999)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

Luteoskyrin [21884-44-6] (Vol. 10, Suppl. 7; 1987)

Madder root (*Rubia tinctorum*) (Vol. 82; 2002)

Magnetic fields (static) (Vol. 80; 2002)

Malathion [121-75-5] (Vol. 30, Suppl. 7; 1987)

Maleic hydrazide [123-33-1] (Vol. 4, Suppl. 7; 1987)

Malonaldehyde [542-78-9] (Vol. 36, Suppl. 7, Vol. 71; 1999)

Maneb [12427-38-2] (Vol. 12, Suppl. 7; 1987)

Mannomustine dihydrochloride [551-74-6] (Vol. 9, Suppl. 7; 1987)

Medphalan [13045-94-8] (Vol. 9, Suppl. 7; 1987)

Melamine [108-78-1] (Vol. 73; 1999)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

6-Mercaptopurine [50-44-2] (Vol. 26, Suppl. 7; 1987)

Mercury [7439-97-6] and inorganic mercury compounds (Vol. 58;1993)

Metabisulfites (Vol. 54; 1992)

Methimazole [60-56-0] (Vol. 79; 2001)

Methotrexate [59-05-2] (Vol. 26, Suppl. 7; 1987)

Methoxychlor [72-43-5] (Vol. 20, Suppl. 7; 1987)

Methyl acrylate [96-33-3] (Vol. 39, Suppl. 7, Vol. 71; 1999)

5-Methylangelicin [73459-03-7] plus ultraviolet A radiation (Suppl.7; 1987)

Methyl bromide [74-83-9] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Methyl tert-butyl ether [1634-04-4] (Vol. 73; 1999)

Methyl carbamate [598-55-0] (Vol. 12, Suppl. 7; 1987)

Methyl chloride [74-87-3] (Vol. 41, Suppl. 7, Vol. 71; 1999)

1-Methylchrysene [3351-28-8] (Vol. 32, Suppl. 7; 1987)

2-Methylchrysene [3351-32-4] (Vol. 32, Suppl. 7; 1987)

3-Methylchrysene [3351-31-3] (Vol. 32, Suppl. 7; 1987)

4-Methylchrysene [3351-30-2] (Vol. 32, Suppl. 7; 1987)

6-Methylchrysene [1705-85-7] (Vol. 32, Suppl. 7; 1987)

N-Methyl-N,4-dinitrosoaniline [99-80-9] (Vol. 1, Suppl. 7; 1987)

4,4'-Methylene bis(N,N-dimethyl)benzenamine [101-61-1](Vol. 27, Suppl. 7; 1987)

4,4'-Methylenediphenyl diisocyanate [101-68-8] (Vol. 19, Suppl. 7, Vol. 71; 1999)

2-Methylfluoranthene [33543-31-6] (Vol. 32, Suppl. 7; 1987)

3-Methylfluoranthene [1706-01-0] (Vol. 32, Suppl. 7; 1987)

Methylglyoxal [78-98-8] (Vol. 51; 1991)

Methyl iodide [74-88-4] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Methyl methacrylate [80-62-6] (Vol. 60; 1994)

N-Methylolacrylamide [90456-67-0] (Vol. 60; 1994)

Methyl parathion [298-00-0] (Vol. 30, Suppl. 7; 1987)

1-Methylphenanthrene [832-69-9] (Vol. 32, Suppl. 7; 1987)

7-Methylpyrido[3,4-c]psoralen [85878-63-3] (Vol. 40, Suppl.7; 1987)

Methyl red [493-52-7] (Vol. 8, Suppl. 7; 1987)

Methyl selenac [144-34-3] (Vol. 12, Suppl. 7; 1987)

Modacrylic fibres (Vol. 19, Suppl. 7; 1987)

Monuron [150-68-5] (Vol. 53; 1991)

Morpholine [110-91-8] (Vol. 47, Vol. 71; 1999)

Musk ambrette [83-66-9] (Vol. 65; 1996)

Musk xylene [81-15-2] (Vol. 65; 1996)

1,5-Naphthalenediamine [2243-62-1] (Vol. 27, Suppl. 7; 1987)

1,5-Naphthalene diisocyanate [3173-72-6] (Vol. 19, Suppl. 7, Vol. 71; 1999)

1-Naphthylamine [134-32-7] (Vol. 4, Suppl. 7; 1987)

1-Naphthylthiourea (ANTU) [86-88-4] (Vol. 30, Suppl. 7; 1987)

Nithiazide [139-94-6] (Vol. 31, Suppl. 7; 1987)

5-Nitro-ortho-anisidine [99-59-2] (Vol. 27, Suppl. 7; 1987)

9-Nitroanthracene [602-60-8] (Vol. 33, Suppl. 7; 1987)

7-Nitrobenz[a]anthracene [20268-51-3] (Vol. 46; 1989)

6-Nitrobenzo[a]pyrene [63041-90-7] (Vol. 46; 1989)

4-Nitrobiphenyl [92-93-3] (Vol. 4, Suppl. 7; 1987)

3-Nitrofluoranthene [892-21-7] (Vol. 33, Suppl. 7; 1987)

Nitrofural (Nitrofurazone) [59-87-0] (Vol. 50; 1990)

Nitrofurantoin [67-20-9] (Vol. 50; 1990)

1-Nitronaphthalene [86-57-7] (Vol. 46; 1989)

2-Nitronaphthalene [581-89-5] (Vol. 46; 1989)

3-Nitroperylene [20589-63-3] (Vol. 46; 1989)

2-Nitropyrene [789-07-1] (Vol. 46; 1989)

N'-Nitrosoanabasine [37620-20-5] (Vol. 37, Suppl. 7; 1987)

N'-Nitrosoanatabine [71267-22-6] (Vol. 37, Suppl. 7; 1987)

N-Nitrosodiphenylamine [86-30-6] (Vol. 27, Suppl. 7; 1987)

para-Nitrosodiphenylamine [156-10-5] (Vol. 27, Suppl. 7;1987)

N-Nitrosofolic acid [29291-35-8] (Vol. 17, Suppl. 7; 1987)

N-Nitrosoguvacine [55557-01-2] (Vol. 85; in preparation)

N-Nitrosoguvacoline [55557-02-3] (Vol. 85; in preparation)

N-Nitrosohydroxyproline [30310-80-6] (Vol. 17, Suppl. 7;1987)

3-(N-Nitrosomethylamino)propionaldehyde [85502-23-4] (Vol. 85; in preparation)

4-(N-Nitrosomethylamino)-4-(3-pyridyl)-1-butanal (NNA) [64091-90-3] (Vol. 37, Suppl. 7; 1987)

N-Nitrosoproline [7519-36-0] (Vol. 17, Suppl. 7; 1987)

Nitrotoluenes [88-72-2; 99-08-1; 99-99-0] (Vol. 65; 1996)

5-Nitro-ortho-toluidine [99-55-8] (Vol. 48; 1990)

Nitrovin [804-36-4] (Vol. 31, Suppl. 7; 1987)

Nylon 6 [25038-54-4] (Vol. 19, Suppl. 7; 1987)

Oestradiol mustard [22966-79-6] (Vol. 9, Suppl. 7; 1987)

Opisthorchis felineus (infection with) (Vol. 61; 1994)

Orange I [523-44-4] (Vol. 8, Suppl. 7; 1987)

Orange G [1936-15-8] (Vol. 8, Suppl. 7; 1987)

Oxyphenbutazone [129-20-4] (Vol. 13, Suppl. 7; 1987)

Palygorskite (attapulgite) [12174-11-7] (short fibres, < 5 micrometers) (Vol. 68; 1997)

Paracetamol (Acetaminophen) [103-90-2] (Vol. 73; 1999)

Parasorbic acid [10048-32-5] (Vol. 10, Suppl. 7; 1987)

Parathion [56-38-2] (Vol. 30, Suppl. 7; 1987)

Patulin [149-29-1] (Vol. 40, Suppl. 7; 1987)

Penicillic acid [90-65-3] (Vol. 10, Suppl. 7; 1987)

Pentachloroethane [76-01-7] (Vol. 41, Suppl. 7, Vol. 71; 1999)

Permethrin [52645-53-1] (Vol. 53; 1991)

Perylene [198-55-0] (Vol. 32, Suppl. 7; 1987)

Petasitenine [60102-37-6] (Vol. 31, Suppl. 7; 1987)

Phenanthrene [85-01-8] (Vol. 32, Suppl. 7; 1987)

Phenelzine sulfate [156-51-4] (Vol. 24, Suppl. 7; 1987)

Phenicarbazide [103-03-7] (Vol. 12, Suppl. 7; 1987)

Phenol [108-95-2] (Vol. 47, Vol. 71; 1999)

Phenylbutazone [50-33-9] (Vol. 13, Suppl. 7; 1987)

meta-Phenylenediamine [108-45-2] (Vol. 16, Suppl. 7; 1987)

para-Phenylenediamine [106-50-3] (Vol. 16, Suppl. 7; 1987)

N-Phenyl-2-naphthylamine [135-88-6] (Vol. 16, Suppl. 7; 1987)

ortho-Phenylphenol [90-43-7] (Vol. 73; 1999)

Picloram [1918-02-1] (Vol. 53; 1991)

Piperonyl butoxide [51-03-6] (Vol. 30, Suppl. 7; 1987)

Polyacrylic acid [9003-01-4] (Vol. 19, Suppl. 7; 1987)

Polychlorinated dibenzo-para-dioxins (other than 2,3,7,8-tetrachlorodibenzo-para-dioxin) (Vol. 69; 1997)

Polychlorinated dibenzofurans (Vol. 69; 1997)

Polychloroprene [9010-98-4] (Vol. 19, Suppl. 7; 1987)

Polyethylene [9002-88-4] (Vol. 19, Suppl. 7; 1987)

Polymethylene polyphenyl isocyanate [9016-87-9] (Vol. 19, Suppl. 7; 1987)

Polymethyl methacrylate [9011-14-7] (Vol. 19, Suppl. 7; 1987)

Polypropylene [9003-07-0] (Vol. 19, Suppl. 7; 1987)

Polystyrene [9003-53-6] (Vol. 19, Suppl. 7; 1987)

Polytetrafluoroethylene [9002-84-0] (Vol. 19, Suppl. 7; 1987)

Polyurethane foams [9009-54-5] (Vol. 19, Suppl. 7; 1987)

Polyvinyl acetate [9003-20-7] (Vol. 19, Suppl. 7; 1987)

Polyvinyl alcohol [9002-89-5] (Vol. 19, Suppl. 7; 1987)

Polyvinyl chloride [9002-86-2] (Vol. 19, Suppl. 7; 1987)

Polyvinyl pyrrolidone [9003-39-8] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Ponceau SX [4548-53-2] (Vol. 8, Suppl. 7; 1987)

Potassium bis(2-hydroxyethyl)dithiocarbamate [23746-34-1] (Vol. 12, Suppl. 7; 1987)

Prazepam [2955-38-6] (Vol. 66; 1996)

Prednimustine [29069-24-7] (Vol. 50; 1990)

Prednisone [53-03-2] (Vol. 26, Suppl. 7; 1987)

Proflavine salts (Vol. 24, Suppl. 7; 1987)

Pronetalol hydrochloride [51-02-5] (Vol. 13, Suppl. 7; 1987)

Propam [122-42-9] (Vol. 12, Suppl. 7; 1987)

n-Propyl carbamate [627-12-3] (Vol. 12, Suppl. 7; 1987)

Propylene [115-07-1] (Vol. 60; 1994)

Ptaquiloside [87625-62-5] (Vol. 40, Suppl. 7; 1987)

Pyrene [129-00-0] (Vol. 32, Suppl. 7; 1987)

Pyridine [110-86-1] (Vol. 77; 2000)

Pyrido[3,4-c]psoralen [85878-62-2] (Vol. 40, Suppl. 7; 1987)

Pyrimethamine [58-14-0] (Vol. 13, Suppl. 7; 1987)

Quercetin [117-39-5] (Vol. 73; 1999)

para-Quinone [106-51-4] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Quintozene (Pentachloronitrobenzene) [82-68-8] (Vol. 5, Suppl. 7; 1987)

Reserpine [50-55-5] (Vol. 24, Suppl. 7; 1987)

Resorcinol [108-46-3] (Vol. 15, Suppl. 7, Vol. 71, 1999)

Retrorsine [480-54-6] (Vol. 10, Suppl. 7; 1987)

Rhodamine B [81-88-9] (Vol. 16, Suppl. 7; 1987)

Rhodamine 6G [989-38-8] (Vol. 16, Suppl. 7; 1987)

Rifampicin [13292-46-1] (Vol. 24, Suppl. 7; 1987)

Ripazepam [26308-28-1] (Vol. 66; 1996)

Rock (stone) wool (Vol. 43, Vol. 81; 2002)

Rugulosin [23537-16-8] (Vol. 40, Suppl. 7; 1987)

Saccharated iron oxide [8047-67-4] (Vol. 2, Suppl. 7; 1987)

Saccharin [81-07-2] and its salts (Vol. 73; 1999)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

Scarlet Red [85-83-6] (Vol. 8, Suppl. 7; 1987)

Schistosoma mansoni (infection with) (Vol. 61; 1994)

Selenium [7782-49-2] and selenium compounds (Vol. 9, Suppl. 7; 1987)

Semicarbazide hydrochloride [563-41-7] (Vol. 12, Suppl. 7; 1987)

Seneciophylline [480-81-9] (Vol. 10, Suppl. 7; 1987)

Senkirkine [2318-18-5] (Vol. 31, Suppl. 7; 1987)

Sepiolite [15501-74-3] (Vol. 68; 1997)

Shikimic acid [138-59-0] (Vol. 40, Suppl. 7; 1987)

Silica [7631-86-9], amorphous (Vol. 68; 1997)

Simazine [122-34-9] (Vol. 73; 1999)

Slag wool (Vol. 43, Vol. 81; 2002)

Sodium chlorite [7758-19-2] (Vol. 52; 1991)

Sodium diethyldithiocarbamate [148-18-5] (Vol. 12, Suppl. 7; 1987)

Spirolactone [52-01-7] (Vol. 79; 2001)

Styrene-acrylonitrile copolymers [9003-54-7] (Vol. 19, Suppl. 7; 1987)

Styrene-butadiene copolymers [9003-55-8] (Vol. 19, Suppl. 7; 1987)

Succinic anhydride [108-30-5] (Vol. 15, Suppl. 7; 1987)

Sudan I [842-07-9] (Vol. 8, Suppl. 7; 1987)

Sudan II [3118-97-6] (Vol. 8, Suppl. 7; 1987)

Sudan III [85-86-9] (Vol. 8, Suppl. 7; 1987)

Sudan Brown RR [6416-57-5] (Vol. 8, Suppl. 7; 1987)

Sudan Red 7B [6368-72-5] (Vol. 8, Suppl. 7; 1987)

Sulfafurazole (Sulfisoxazole) [127-69-5] (Vol. 24, Suppl. 7; 1987)

Sulfamethazine [57-68-1] (Vol. 79; 2001)(NB: Overall evaluation downgraded from 2B to 3 with supporting evidence from other data relevant to carcinogenicity and its mechanisms)

Sulfamethoxazole [723-46-6] (Vol. 79; 2001)

Sulfites (Vol. 54; 1992)

Sulfur dioxide [7446-09-5] (Vol. 54; 1992)

Sunset Yellow FCF [2783-94-0] (Vol. 8, Suppl. 7; 1987)

Surgical implants (Vol. 74; 1999)

Orthopaedic implants and devices, of complex composition
Cardiac pacemakers
Dental materials
Ceramic materials

Surgical implants, female breast reconstruction, silicone (Vol. 74; 1999)

Symphytine [22571-95-5] (Vol. 31, Suppl. 7; 1987)

Talc [14807-96-6], not containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)

Tannic acid [1401-55-4] and tannins (Vol. 10, Suppl. 7; 1987)

Temazepam [846-50-4] (Vol. 66; 1996)

2,2',5,5'-Tetrachlorobenzidine [15721-02-5] (Vol. 27, Suppl. 7; 1987)

1,1,1,2-Tetrachloroethane [630-20-6] (Vol. 41, Suppl. 7, Vol. 71; 1999)

1,1,2,2-Tetrachloroethane [79-34-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)

Tetrachlorvinphos [22248-79-9] (Vol. 30, Suppl. 7; 1987)

Tetrakis(hydroxymethyl)phosphonium salts (Vol. 48, Vol. 71; 1999)

Theobromine [83-67-0] (Vol. 51; 1991)

Theophylline [58-55-9] (Vol. 51; 1991)

Thiourea [62-56-6] (Vol. 79; 2001)

Thiram [137-26-8] (Vol. 53; 1991)

Titanium dioxide [13463-67-7] (Vol. 47; 1989)

Toluene [108-88-3] (Vol. 47, Vol. 71; 1999)

Toremifene [89778-26-7] (Vol. 66; 1996)

Toxins derived from *Fusarium graminearum*, *F. culmorum* and *F. crookwellense* (Vol. 56; 1993)

Toxins derived from *Fusarium sporotrichioides* (Vol. 56; 1993)

Trichlorfon [52-68-6] (Vol. 30, Suppl. 7; 1987)

Trichloroacetic acid [76-03-9] (Vol. 84; in preparation)

Trichloroacetonitrile [545-06-2] (Vol. 52, Vol. 71; 1999)

1,1,1-Trichloroethane [71-55-6] (Vol. 20, Suppl. 7, Vol. 71; 1999)

1,1,2-Trichloroethane [79-00-5] (Vol. 52, Vol. 71; 1999)

Triethanolamine [102-71-6] (Vol. 77; 2000)

Triethylene glycol diglycidyl ether [1954-28-5] (Vol. 11, Suppl. 7, Vol. 71; 1999)

Trifluralin [1582-09-8] (Vol. 53; 1991)

4,4',6-Trimethylangelicin [90370-29-9] plus ultraviolet A radiation (Suppl. 7; 1987)

2,4,5-Trimethylaniline [137-17-7] (Vol. 27, Suppl. 7; 1987)

2,4,6-Trimethylaniline [88-05-1] (Vol. 27, Suppl. 7; 1987)

4,5',8-Trimethylpsoralen [3902-71-4] (Vol. 40, Suppl. 7; 1987)

2,4,6-Trinitrotoluene [118-96-7] (Vol. 65; 1996)

Triphenylene [217-59-4] (Vol. 32, Suppl. 7; 1987)

Tris(aziridinyl)-para-benzoquinone (Triaziqnone) [68-76-8] (Vol. 9, Suppl. 7; 1987)

Tris(1-aziridinyl)phosphine oxide [545-55-1] (Vol. 9, Suppl. 7; 1987)

2,4,6-Tris(1-aziridinyl)-s-triazine [51-18-3] (Vol. 9, Suppl. 7; 1987)

Tris(2-chloroethyl) phosphate [115-96-8] (Vol. 48, Vol. 71; 1999)

1,2,3-Tris(chloromethoxy)propane [38571-73-2] (Vol. 15, Suppl. 7, Vol. 71; 1999)

Tris(2-methyl-1-aziridinyl)phosphine oxide [57-39-6] (Vol. 9, Suppl. 7; 1987)

Vat Yellow 4 [128-66-5] (Vol. 48; 1990)

Vinblastine sulfate [143-67-9] (Vol. 26, Suppl. 7; 1987)

Vincristine sulfate [2068-78-2] (Vol. 26, Suppl. 7; 1987)

Vinyl chloride-vinyl acetate copolymers [9003-22-9] (Vol. 19, Suppl. 7; 1987)

Vinylidene chloride [75-35-4] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Vinylidene chloride-vinyl chloride copolymers [9011-06-7] (Vol.19, Suppl. 7; 1987)

Vinylidene fluoride [75-38-7] (Vol. 39, Suppl. 7, Vol. 71; 1999)

N-Vinyl-2-pyrrolidone [88-12-0] (Vol. 19, Suppl. 7, Vol. 71; 1999)

Vinyl toluene [25013-15-4] (Vol. 60; 1994)

Vitamin K [12001-79-5] substances (Vol. 76; 2000)

Wollastonite [13983-17-0] (Vol. 68; 1997)

Xylenes [1330-20-7] (Vol. 47, Vol. 71; 1999)

2,4-Xylidine [95-68-1] (Vol. 16, Suppl. 7; 1987)

2,5-Xylidine [95-78-3] (Vol. 16, Suppl. 7; 1987)

Yellow AB [85-84-7] (Vol. 8, Suppl. 7; 1987)

Yellow OB [131-79-3] (Vol. 8, Suppl. 7; 1987)

Zectran [315-18-4] (Vol. 12, Suppl. 7; 1987)

Zeolites [1318-02-1] other than erionite (clinoptilolite, phillipsite, mordenite, non-fibrous Japanese zeolite, synthetic zeolites) (Vol.68; 1997)

Zineb [12122-67-7] (Vol. 12, Suppl. 7; 1987)

Ziram [137-30-4] (Vol. 53; 1991)

Mixtures

Bitumens [8052-42-4], steam-refined, cracking-residue and air-refined (Vol. 35, Suppl. 7; 1987)

Crude oil [8002-05-9] (Vol. 45; 1989)

Diesel fuels, distillate (light) (Vol. 45; 1989)

Fuel oils, distillate (light) (Vol. 45; 1989)

Jet fuel (Vol. 45; 1989)

Mate (Vol. 51; 1991)

Mineral oils, highly-refined (Vol. 33, Suppl. 7; 1987)

Petroleum solvents (Vol. 47; 1989)

Printing inks (Vol. 65; 1996)

Tea (Vol. 51; 1991)

Terpene polychlorinates (Strobane®) [8001-50-1] (Vol. 5, Suppl. 7; 1987)

Exposure circumstances

Flat-glass and specialty glass (manufacture of) (Vol. 58; 1993)

Hair colouring products (personal use of) (Vol. 57; 1993)

Leather goods manufacture (Vol. 25, Suppl. 7; 1987)

Leather tanning and processing (Vol. 25, Suppl. 7; 1987)

Lumber and sawmill industries (including logging) (Vol. 25, Suppl.7; 1987)

Paint manufacture (occupational exposure in) (Vol. 47; 1989)

Pulp and paper manufacture (Vol. 25, Suppl. 7; 1987)

Group 4: Probably not carcinogenic to humans (1)

Caprolactam [105-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1999)

Last updated: 22 July 2004